Abstract
Background The 2030 target for schistosomiasis is elimination as a public health problem (EPHP), achieved when the prevalence of heavy intensity infection among school-aged children (SAC) reduces to <1%. To achieve this, the new World Health Organization (WHO) guidelines recommend a broader target of population to include pre-school (pre-SAC) and adults. However, the probability of achieving EPHP should be expected to depend on patterns in repeated uptake of mass drug administration (MDA) by individuals.
Methods We employed two individual-based stochastic models to evaluate the impact of school-based and community-wide treatment and calculated the number of rounds required to achieve EPHP for Schistosoma. mansoni by considering various levels of the population never treated (NT). We also considered two age intensity profiles, corresponding to a low and high burden of infection in adults.
Results The number of rounds needed to achieve this target depends on the baseline prevalence and the coverage used. For low and moderate transmission areas, EPHP can be achieved within seven years if NT ≤10% and NT <5%, respectively. In high transmission areas, community wide treatment with NT<1% is required to achieve EPHP.
Conclusions The higher the intensity of transmission, and the lower the treatment coverage, the lower the acceptable value of NT becomes. Using more efficacious treatment regimens would permit NT values to be marginally higher. A balance between target treatment coverage and NT values may be an adequate treatment strategy depending on the epidemiological setting, but striving to increase coverage and/or minimise NT can shorten programme duration.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors are grateful for funding by the Bill & Melinda Gates Foundation through the NTD Modelling Consortium (grant INV-030046).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Co-first authors
Data Availability
All data produced in the present work are contained in the manuscript
Abbreviations
- epg
- eggs per gram of faeces
- EPHP
- elimination as a public health problem
- EPHP90
- probability of reaching EPHP in 90% of model runs
- EOT
- elimination of transmission
- MDA
- mass drug administration
- NT
- proportion (of eligibles) never treated
- NTD
- neglected tropical disease
- pre-SAC
- pre-school age children
- PZQ
- praziquantel
- R0
- basic reproduction number
- SAC
- school-age children
- WHO
- World Health Organization
